Metabolic syndrome

Medicine

Volumn 39, Issue 1, 2011, Pages 24-31

  Han, T S ^a   Lean, M E J ^b  

^a ASHFORD AND ST PETER'S HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

adipokines; cardiovascular disease; diabetes; hypogonadism; insulin resistance; lipodystrophy; muscle atrophy; obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BROMOCRIPTINE MESILATE; C REACTIVE PROTEIN; EXENDIN 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; RESISTIN; SIBUTRAMINE; SITAGLIPTIN; TESTOSTERONE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; VILDAGLIPTIN;

AGE; ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY FAT DISTRIBUTION; BODY MASS; CARDIOVASCULAR DISEASE; CUSHING SYNDROME; DEPRESSION; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; EXERCISE; FETUS GROWTH; GENETICS; GLUCOSE INTOLERANCE; HEREDITY; HUMAN; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOXIA; IMMOBILIZATION; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID STORAGE; LIPODYSTROPHY; METABOLIC DISORDER; METABOLIC SYNDROME X; MUSCLE; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SLEEP APNEA SYNDROME; SLEEP DISORDER; SMOKING; SOCIAL STATUS; SPINAL CORD INJURY; STRESS; SUBCUTANEOUS FAT; UTERUS GROWTH; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT GAIN;

EID: 78650685305     PISSN: 13573039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpmed.2010.10.010     Document Type: Review

References (32)

1. W.B. Kannel, D. McGee, and T. Gordon A general cardiovascular risk profile: the Framingham study Am J Cardiol 38 1976 46 51
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel detection, evaluation, and treatment of high blood cholesterol adults (Adult Treatment Panel III) J Am Med Assoc 285 2001 2486 2497
3. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome [article online: www.idf.org ].
4. D.A. Lawlor, M.E. Lean, and N.A. Sattar Obesity and a wider impact on vascular disease BMJ 18 2006 1060 1063
5. C. Bouchard Genetics and the metabolic syndrome Int J Obes 19 suppl 1 1995 S52 S59
6. T.S. Han, F.C. Bijnen, M.E. Lean, and J.C. Seidell Separate associations of waist and hip circumference with lifestyle factors Int J Epidemiol 27 1998 422 430
7. R.K. Semple, V.K. Chatterjee, and S. O'Rahilly PPAR gamma and human metabolic disease J Clin Invest 116 2006 581 589
8. J.M. Guettier, J.Y. Park, and E.K. Cochran Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation Clin Endocrinol 68 2008 547 554
9. U.A. Walker, M. Kirschfink, and H.H. Peter Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation Rheumatology 42 2003 393 394
10. F.C.W. Wu, A. Tajar, and J.M. Beynon for the EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men N Engl J Med June 16, 2010 10.1056/NEJMoa0911101
11. V. Kupelian, F.J. Hayes, C.L. Link, R. Rosen, and J.B. McKinlay Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups J Clin Endocrinol Metab 93 2008 3403 3410
12. E. Tasali, and M.S. Ip Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation Proc Am Thorac Soc 5 2008 207 217
13. S.G. Wannamethee, A.G. Shaper, and A. Rumley Lung function and risk of type 2 diabetes and fatal and non-fatal major coronary heart disease events: possible associations with inflammation Diabetes Care June 2, 2010 10.2337/dc10-0324
14. D.J.P. Barker Fetal and infant origins of adult disease 1992 Springer Publishing London
15. T.S. Han, N. Sattar, K. Williams, C. Gonzalez-Villalpando, and S.M. Lean Haffner Prospective study of C-reactive protein in relation the development of diabetes and the metabolic syndrome in city diabetes study Diabetes Care 25 2002 2016 2021
16. A. Astrup, S. Rössner, and L. Van Gaal NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 2009 1606 1616
17. R.E. Scranton, J.M. Gaziano, D. Rutty, M. Ezrokhi, and A. Cincotta A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either cycloset or placebo BMC Endocr Disord 7 2007 3
18. A.H. Cincotta, A.H. Meier, and M. Cincotta Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes Expert Opin Investig Drugs 8 1999 1683 1707
19. H. Pijl, and A.M. Edo Modulation of monoaminergic neural circuits: potential for the treatment of type 2 diabetes mellitus Treat Endocrinol 1 2002 71 78
20. C.M. Gregory, K. Vandenborne, H.F. Huang, J.E. Ottenweller, and G.A. Dudley Effects of testosterone replacement therapy on skeletal muscle after spinal cord injury Spinal Cord 41 2003 23 28
21. T. Ogata, Y. Nakamura, K. Tsuji, T. Shibata, and K. Kataoka Steroid hormones protect spinal cord neurons from glutamate toxicity Neuroscience 55 1993 445 449
22. E.A. Sribnick, J.M. Wingrave, D.D. Matzelle, S.K. Ray, and N.L. Banik Estrogen as a neuroprotective agent in the treatment of spinal cord injury Ann N Y Acad Sci 993 2003 125 133
23. A.E. Heufelder, F. Saad, M.C. Bunck, and L. Gooren Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone J Androl 30 2009 726 733
24. A. Haider, L.J. Gooren, P. Padungtod, and F. Saad Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate Exp Clin Endocrinol Diabetes 118 2010 167 171
25. T.P. Didangelos, A.K. Thanopoulou, and S.H. Bousboulas The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study Curr Med Res Opin 20 2004 1393 1401
26. M. Nieuwdorp, E.S. Stroes, and J.J. Kastelein Fenofibrate/Metformin Study Group. Normalization of metabolic syndrome using fenofibrate, metformin or their combination Diabetes Obes Metab 9 2007 869 878
27. R. Abu-Hamdah, A. Rabiee, G.S. Meneilly, R.P. Shannon, D.K. Andersen, and D. Elahi Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides J Clin Endocrinol Metab 94 2009 1843 1852
28. P. Björntorp, International textbook of obesity 2001 Wiley Chichester
29. L. Gooren, S. Meryn, and R. Shabsigh The metabolic syndrome: when is testosterone treatment warranted J Mens Health 5 2008 S40 S45
30. A. Lucas Programming by early nutrition in man G.R. Bock, J. Whelan, The childhood environment and adult disease 1991 Wiley Chichester 38 55
31. G.M. Reaven Banting Lecture. Role of insulin resistance in human disease Diabetes 1988 37 1988 1595 1607
32. N. Sattar, and M.E.J. Lean ABC of obesity 2007 BMJ Books London